should you change injection sites for semaglutide The MedHealth 360 Guide to Locations Stomach, Thigh, or Arm: What's

Common menstrual changes associated with weight loss (which may occur during Saxenda treatment) include: Return of regular cycles: Women with obesity-related amenorrhoea or oligomenorrhoea may find their periods become more regular as weight decreases Temporary irregularity: Some women experience irregular cycles during the active weight loss phase, which typically stabilise once weight plateaus Changes in flow: Menstrual bleeding may become lighter or heavier, though this varies individually Altered cycle length: The time between periods may shorten or lengthen temporarily These changes typically reflect the body's metabolic and hormonal adjustment to weight loss rather than a direct drug effect

Bile acids, certain amino acids, like leucine, and GHR have all been found to have receptors or signalling mechanisms in the CNS and to regulate either feeding behaviour or glucose control

Once denatured, the medication may lose its ability to bind effectively to GLP-1 receptors, reducing or eliminating its therapeutic effect on blood glucose control and appetite regulation

The FDA labeling for all semaglutide formulations notes that GLP-1 receptor agonists delay gastric emptying, which could affect the absorption of oral medications

Semaglutide, for example, has been shown in trials to cut the risk of cardiovascular problems such as heart attack and stroke in people who are overweight or have obesity, and to cut the risk of complications from kidney disease in people with Type 2 diabetes